Marina gets $15M commitment; Merck dumps osteoporosis program;

 @FierceBiotech: Twitter opinions linked to vaccine uptake. Item | Follow @FierceBiotech

 @JohnCFierce: My first reaction to the Anadys deal? Looks like Roche is figuring that if it's worth anything, they got it cheap. Article | Follow @JohnCFierce

 @RyanMFierce: FDA extends halt that began in August on Insmed's trial for inhaled antibiotic. $INSM stock takes hit. Story | Follow@RyanMFierce

 @MaureenFierce: Tech needed to stop Twitter from becoming platform for pushers of fake, substandard drugs. Article By @Nick__Taylor. | Follow @MaureenFierce

> Marina Biotech's shares managed to rally a few cents this morning as the cash-starved RNAi developer announced that an investor had agreed to sink up to $15 million in the biotech. Like a number of companies operating in the RNAi arena, Marina has been struggling to overcome mounting questions over the time and effort needed to bring a treatment to approval. But Lincoln Park Capital Fund, an investor in Bothell, WA-based Marina, agreed to buy up to $15 million worth of Marina's shares, extending the developer's runway as it advances its development programs. Marina's shares ($MRNA) were trading at 18 cents this morning after the news hit. Release

> Merck ($MRK) has decided to dump a partnership it struck three years ago with Japan Tobacco on an experimental new drug for osteoporosis. The Japanese company says it will now shelve the program.  Story

> Little Falls, NJ-based Sentrx says that Charles T. Saldarini has resigned his position as CEO and chairman of the board to pursue efforts with his own company. Release

Pharma News

 @FiercePharma: Digesting $13B Nycomed buyout, #Takeda chief says Japanese managers aren't adept at integrating acquisitions - WSJ.Report | Follow @FiercePharma

> Jury clears J&J in another Levaquin injury case. Story

> Healthcare's budget-cutting idea: Target drug companies. Report

> Takeda's plate full with Nycomed integration. Article

> Par Pharma sues FDA, claiming free speech rights. News

Medical Device News

> Boston Sci launches Promus Element stent system in China. Article

> Eucomed to launch conference pre-vetting system. Story

> Analyst names medtech firms ripe for M&A. Report

Biotech IT News

> Google Earth marks sources of infection. Article

> Robot scientist passes big bio test. Story

> Bayer tackles informatics challenges in cancer research. News

> Accelrys brings drug discovery projects to the cloud. Report

> Google VC unit takes lead role DNAnexus's $15M round, hosting huge DNA database. Item

And Finally... Researchers at Washington University School of Medicine say they have discovered why powerful opioids often cause an itching sensation and figured out a way to avoid it. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.